Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 13/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.41 |
| ▸ | KLK7 | P49862 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.40 |
| ▸ | F7 | P08709 | 1/20 | 0.39 |
| ▸ | F3 | P13726 | 1/20 | 0.39 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.39 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2862103 | 0.84 | MKNK1 (0.49) | TGFBR1MKNK1HSD11B1KLK7DYRK1A | |
| SCHEMBL29893844 | 0.84 | MKNK1 (0.49) | TGFBR1MKNK1HSD11B1KLK7DYRK1A | |
| Hydrochloric Acid SCHEMBL30152411 | 0.82 | MKNK1 (0.47) | TGFBR1MKNK1HSD11B1KLK7DYRK1A | |
| SCHEMBL1691581 | 0.82 | MKNK1 (0.47) | TGFBR1MKNK1HSD11B1KLK7DYRK1A | |
| SCHEMBL30100800 | 0.82 | MKNK1 (0.47) | TGFBR1MKNK1HSD11B1KLK7DYRK1A | |
| SCHEMBL31218862 | 0.81 | MKNK1 (0.44) | TGFBR1MKNK1HSD11B1KLK7DYRK1A | |
| Potassium Ion SCHEMBL31218825 | 0.81 | HSD11B1 (0.47) | TGFBR1MKNK1HSD11B1KLK7DYRK1A | |
| SCHEMBL6279707 | 0.80 | MKNK1 (0.43) | MKNK1HSD11B1KLK7DYRK1AFYN | |
| SCHEMBL22891212 | 0.78 | HSD11B1 (0.51) | TGFBR1MKNK1HSD11B1KLK7DYRK1A | |
| SCHEMBL4569221 | 0.78 | MKNK1 (0.44) | TGFBR1MKNK1HSD11B1KLK7DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114555604-B | Pharmaceutical compounds | 辉瑞公司 | 2024-11-15 | — | — | CN | claimed |
| CN-112805062-B | Imidazo [1,2-b ] pyridazines as Trk inhibitors | 博善人工智能生物科技有限公司 | 2024-06-04 | — | — | CN | claimed |
| EP-3840832-B1 | IMIDAZO[1,2-B]PYRIDAZINES AS TRK INHIBITORS | BENEVOLENTAI BIO LTD (GB) | 2023-10-11 | — | — | EP | claimed |
| EP-3672952-B1 | BENZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-12-14 | — | — | EP | claimed |
| CN-115297863-A | Topical pharmaceutical compositions comprising imidazo [1,2-b ] pyridazine compounds | 博善人工智能生物科技有限公司 | 2022-11-04 | — | — | CN | claimed |
| EP-4017856-A1 | PHARMACEUTICAL COMPOUNDS | Reviral Limited (GB) | 2022-06-29 | — | — | EP | claimed |
| US-11352360-B2 | TGF-beta inhibitors | Rigel Pharmaceuticals, hic. (US) | 2022-06-07 | — | — | US | claimed |
| US-12338242-B2 | TYK2 inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-06-24 | — | — | US | disclosed |
| US-12227507-B2 | Pharmaceutical compounds | PFIZER INC. (US) | 2025-02-18 | — | — | US | disclosed |
| CN-119013277-A | TYK2 degrading agent and application thereof | 凯麦拉医疗公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-114555604-B | Pharmaceutical compounds | 辉瑞公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118742552-A | Five-membered and six-membered heterocyclic compounds and application thereof as protein kinase inhibitors | 上海轶诺药业有限公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-118359618-A | Hydrazide substituted condensed heteroaryl compounds, preparation method and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2024-07-19 | — | — | CN | disclosed |
| US-20160214986-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2016-07-28 | — | — | US | disclosed |
| EP-3010922-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Galapagos NV (BE) | 2016-04-27 | — | — | EP | disclosed |
| WO-2014202458-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2014-12-24 | — | — | WO | disclosed |
| EP-2802590-A1 | THIENOPYRIMIDINE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2014-11-19 | — | — | EP | disclosed |
| WO-2013104575-A1 | THIENOPYRIMIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-07-18 | — | — | WO | disclosed |
| EP-2614062-A1 | IMIDAZO [1, 2]PYRIDAZIN COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012034091-A1 | IMIDAZO [1, 2] PYRIDAZIN COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352360-B2 | TGF-beta inhibitors | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885MKNK1 2360/4885HSD11B1 1457/4885 |
| US-12227507-B2 | Pharmaceutical compounds | CHRNA6, GABRA6, CHRNA7 | TGFBR1 858/4885MKNK1 4661/4885HSD11B1 815/4885 |
| US-20160214986-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ENPP2, TPX2, PRXL2A | TGFBR1 2446/4885MKNK1 4445/4885HSD11B1 3383/4885 |
| US-12338242-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | TGFBR1 1802/4885MKNK1 216/4885HSD11B1 3406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.